"10.1371_journal.pone.0042209","plos one","2012-07-27T00:00:00Z","Pascal Poignard; Brian Moldt; Karla Maloveste; Noëlie Campos; William C Olson; Eva Rakasz; David I Watkins; Dennis R Burton","Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America; International AIDS Vaccine Initiative, New York, New York, United States of America; The Centre dImmunologie de Marseille-Luminy, and Institut National de la Santé et de la Recherche Medicale, and Centre National de la Recherche Scientifique, Marseille, France; Progenics Pharmaceuticals, Inc. Tarrytown, New York, United States of America; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Department of Pathology, University of Miami, Miami, Florida, United States of America; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Boston, Massachusetts, United States of America","¤a Current address: Amplimmune, Inc, Gaithersburg, Maryland, United States of America","WCO owns stock in and is employed by Progenics Pharmaceuticals Inc. and is an inventor on patents involving the use ofCD4-IgG2 (Patent no. 7,736,649 June 15,2010; 7,138,119 November 21, 2006; 7,070,991 July 4, 2006; 6,737,267 May 18,2004; 6,451,313 September 17, 2002; 6,187,748 February 13, 2001; 6,177,549 January 23, 2001; 6,034,223 March 7, 2000; 5,817,767 October 6, 1998). The remaining authors have declared that no competing interests exist. This does not alter the authors′ adherence to all the PLoS ONE policies on sharing data and materials. There are no further products in development or marketed products to declare.","2012","07","Pascal Poignard","PP",8,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
